NR3C2 and hypertensive disorder: We conclude that while standard care for CKD mandates use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, the addition of a safe nonsteroidal MRA can help mitigate CKD progression and treat hypertension caused by aldosterone activation of mineralocorticoid receptors.